Nemonapride
Antipsychotic medication / From Wikipedia, the free encyclopedia
Nemonapride (エミレース, Emilace (JP)) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in May 1991.[1] Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist.[2] It has affinity for sigma receptors.
This article needs additional citations for verification. (July 2022) |
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Emilace (JP) |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C21H26ClN3O2 |
Molar mass | 387.91 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Close